Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist Financial

Key Points

• Truist cut its Agios price target from $37 to $35 but maintained a Buy rating; the new target implies about 19.6% upside from the share price cited in the report.
• Analyst sentiment remains broadly positive: MarketBeat reports a Moderate Buy consensus and an average price target of $42.12, with HC Wainwright recently raising its target to $62.
• Agios beat quarterly estimates, reporting a loss of $1.09 per share versus the $1.24 expected and revenue of $55.39 million versus $51.65 million forecast.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) had its price objective dropped by equities researchers at Truist Financial from $37.00 to $35.00 in a report released on Friday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Truist Financial's price objective suggests a potential upside of 19.64% from the company's current price.

AGIO has been the subject of a number of other reports. Bank of America upped their price target on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a "buy" rating in a report on Monday, September 21st. TD Cowen raised shares of Agios Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 24th. HC Wainwright boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $62.00 and gave the stock a "buy" rating in a report on Friday. Citigroup increased their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $42.12.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded up $0.98 during trading on Friday, hitting $29.25. The stock had a trading volume of 439,928 shares, compared to its average volume of 1,073,670. The business has a fifty day moving average of $33.37 and a two-hundred day moving average of $31.75. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The firm has a market cap of $1.75 billion, a P/E ratio of -4.16 and a beta of 0.66.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.24) by $0.15. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The firm had revenue of $55.39 million for the quarter, compared to analyst estimates of $51.65 million. As a group, research analysts forecast that Agios Pharmaceuticals will post -5.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Sarah Gheuens sold 7,866 shares of the stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the completion of the sale, the insider directly owned 54,645 shares of the company's stock, valued at approximately $2,059,570.05. This represents a 12.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,855 shares of company stock worth $371,112 over the last quarter. 5.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of large investors have recently made changes to their positions in AGIO. Three Bridge Wealth Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth about $27,000. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $1,020,000. Lido Advisors LLC acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $411,000. Fulcrum Asset Management LLP bought a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $94,000. Finally, AlphaCentric Advisors LLC grew its stake in shares of Agios Pharmaceuticals by 3.9% in the 3rd quarter. AlphaCentric Advisors LLC now owns 14,731 shares of the biopharmaceutical company's stock valued at $490,000 after buying an additional 558 shares in the last quarter.

Key Stories Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $62 from $55 and reiterated a Buy rating, signaling greater confidence in Agios’ prospects. HC Wainwright ratings
• Positive Sentiment: Agios beat Q3 estimates, reporting a loss of $1.09 per share versus the $1.24 consensus and revenue of $55.39 million versus expectations of $51.65 million. The loss also narrowed from $1.78 per share a year earlier. Agios Q3 results and business update
• Positive Sentiment: Mitapivat revenue increased more than fourfold, pointing to strong commercial momentum for the drug. Mitapivat revenue and FDA timeline
• Neutral Sentiment: The FDA decision on mitapivat for sickle cell disease is expected in February 2027. The timeline gives investors a milestone to watch, though approval remains uncertain. Mitapivat revenue and FDA timeline
• Negative Sentiment: Agios plans to eliminate more than 100 R&D roles, a significant restructuring that could raise concerns about research capacity even as it may reduce costs. Agios R&D job cuts

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company's research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios' principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.